drugset / Trial / NCT00487136

Interaction Between ABT-335, Rosuvastatin and Warfarin

NCT00487136

Phase 1 Completed 45 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multiple-dose, double-blind, randomized, single-center, parallel-group study in adult male subjects in general good health.

Timeline

Start
2007-06
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-335 Small molecule 135 mg
Subject Rosuvastatin Small molecule 5 mg
Subject Rosuvastatin Small molecule 20 mg
Comparator Warfarin Small molecule

Indications

No indication recorded.